Empagliflozin-Induced Changes in Epicardial Fat: The Centerpiece for Myocardial Protection?
- PMID: 34325889
- DOI: 10.1016/j.jchf.2021.05.006
Empagliflozin-Induced Changes in Epicardial Fat: The Centerpiece for Myocardial Protection?
Keywords: CMR; SGLT2-inhibitors; epicardial adipose tissue; heart failure; myocardial fibrosis.
Conflict of interest statement
Funding Support and Author Disclosures Drs Mullens and Martens have served on advisory boards for AstraZeneca and Boehringer Ingelheim.
Comment on
-
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.JACC Heart Fail. 2021 Aug;9(8):578-589. doi: 10.1016/j.jchf.2021.04.014. JACC Heart Fail. 2021. PMID: 34325888 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical